Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aceragen, Inc.ACGN · Entity 110652 | Director | August 10, 2023 | August 11, 2023 |
| Aclaris Therapeutics, Inc.ACRS · Entity 5041 | Director | June 04, 2026 | June 08, 2026 |
| BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315 | Director | August 31, 2026 | September 02, 2026 |
| Vanda Pharmaceuticals Inc.VNDA · Entity 5861 | Director | June 13, 2018 | June 15, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aceragen, Inc.
Report date August 10, 2023 · Filed August 11, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,987 |
Reported balance
After 2023-08-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-08-10 · Sale · Disposed 3,283 · Balance 8,987 F1: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $0.52 to $0.5513 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: The shares reported on this Form 4 have been adjusted to reflect the Issuer's 1-for-17 reverse stock split of its common stock, effective January 17, 2023. F3: Of the reported securities beneficially owned, 544 shares are represented by unvested Restricted Stock Units. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $0.52 to $0.5513 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: The shares reported on this Form 4 have been adjusted to reflect the Issuer's 1-for-17 reverse stock split of its common stock, effective January 17, 2023.
F3: Of the reported securities beneficially owned, 544 shares are represented by unvested Restricted Stock Units.
Aclaris Therapeutics, Inc.
Report date June 04, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 28,896 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Exercise / conversion · Acquired 11,580 · Balance 28,896 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.71 · Expires 2036-06-03 | Direct | 42,350 |
Reported balance
After 2026-06-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-04 · Grant · Acquired 42,350 · Balance 42,350 F2: The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date. F3: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 10,987 |
Reported balance
After 2026-06-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-04 · Grant · Acquired 10,987 · Balance 10,987 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4: The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date. F3: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-05 · Exercise / conversion · Disposed 11,580 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5: The shares underlying these restricted stock units vested on June 5, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2: The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date.
F3: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy.
F4: The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date.
F5: The shares underlying these restricted stock units vested on June 5, 2026.
BIOCRYST PHARMACEUTICALS INC
Report date August 31, 2026 · Filed September 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 109,642 |
Reported balance
After 2026-08-31 transaction · row 1
1 source rowRow 1 · 2026-08-31 · Grant · Acquired 1,159 · Balance 109,642 F1: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Chair retainer of $22,500. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Chair retainer of $22,500.
Vanda Pharmaceuticals Inc.
Report date June 13, 2018 · Filed June 15, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,000 |
Reported balance
After 2018-06-13 transaction · row 1
1 source rowRow 1 · 2018-06-13 · Grant · Acquired 5,000 · Balance 10,000 F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 13, 2019, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.30 · Expires 2028-06-12 | Direct | 10,000 |
Reported balance
After 2018-06-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-06-13 · Grant · Acquired 10,000 · Balance 10,000 F2: This option vests and becomes exercisable with respect to 100% of the option shares on June 13, 2019, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 13, 2019, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date.
F2: This option vests and becomes exercisable with respect to 100% of the option shares on June 13, 2019, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Spark Therapeutics, Inc.
Report date December 17, 2019 · Filed December 17, 2019
Section 16 reporting ended · disclosed 2019-12-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 1
1 source rowRow 1 · 2019-12-17 · Other · Disposed 3,000 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $81.53 · Expires 2028-05-29 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-12-17 · Disposition to issuer · Disposed 4,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.93 · Expires 2027-05-30 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-12-17 · Disposition to issuer · Disposed 4,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.22 · Expires 2026-05-31 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-12-17 · Disposition to issuer · Disposed 6,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.45 · Expires 2024-08-11 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-12-17 · Disposition to issuer · Disposed 37,203 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn.
F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2022 Filed Apr 4, 2022 17:42 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 99,000 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001415889-22-003750 · form4-04042022_020430.xml · derivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,000 Underlying: Common Stock · 99,000 shares Expires 2032-04-01 F1 · derivative.exercise_date: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option will vest and become exercisable in full on January 24, 2026, with 25% vesting on January 24, 2023, and the remainder vesting in twelve equal quarterly installments over the remaining three years, subject to continued service with the Issuer. Read SEC document |
| January 24, 2022 Filed Jan 26, 2022 20:40 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001415889-22-000790 · form4-01262022_050112.xml · derivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-01-24 F1 · derivative.exercise_date: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 24, 2022. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 24, 2023 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| November 24, 2021 Filed Nov 24, 2021 23:35 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | PurchaseCommon Stock | 7,500 | $12.19 | $91,425.00 |
DisclosureSEC source: 0001171843-21-008177 · ownership.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Read SEC document |
| July 26, 2021 Filed Jul 28, 2021 22:31 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantNon-Qualified Stock Option · Derivative | 66,667 | $0.00 Strike: $17.25 | $0.00 |
DisclosureSEC source: 0001127602-21-022567 · form4.xml · derivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,667 Underlying: Common Stock · 66,667 shares Expires 2031-07-26 F1 · shares: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Amended and Restated Stock Incentive Plan. F2 · derivative.exercise_date: The option vests 1/36 per month for a period of 36 months, beginning on August 26, 2021. Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 16:05 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 124,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001415889-21-003587 · form4-07122021_040718.xml · derivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,000 Underlying: Common Stock · 124,000 shares Expires 2031-07-08 F1 · derivative.exercise_date: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on July 8, 2021. Twenty-five percent (25%) of the stock option vests and becomes exercisable on July 8, 2022 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| June 03, 2021 Filed Jun 5, 2021 00:02 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted Stock Units · Derivative | 3,356 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-038450 · doc4.xml · derivative · entry 2 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,356 Underlying: Common Stock · 3,356 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F1 · derivative.exercise_date: This grant was made pursuant to the issuer's fifth amended and restated non-employee director compensation policy. F4 · derivative.exercise_date: The shares underlying these restricted stock units will vest on June 3, 2022, subject to the Reporting Person's continuous service through such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units will vest on June 3, 2022, subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 03, 2021 Filed Jun 5, 2021 00:02 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantStock Option (Right to Buy) · Derivative | 12,250 | $0.00 Strike: $21.90 | $0.00 |
DisclosureSEC source: 0001209191-21-038450 · doc4.xml · derivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Underlying: Common Stock · 12,250 shares Expires 2031-06-02 F1 · derivative.exercise_date: This grant was made pursuant to the issuer's fifth amended and restated non-employee director compensation policy. F2 · derivative.exercise_date: The shares subject this option will vest in twelve equal monthly installments commencing July 3, 2021, subject to Reporting Person's continuous service through each such date. Read SEC document |
| January 12, 2021 Filed Jan 12, 2021 19:00 UTC | Aceragen, Inc. IDRA · Entity 110652 | SaleCommon Stock | 3,210 | $4.20 | $13,474.30 |
DisclosureSEC source: 0001179110-21-000560 · edgar.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,611 F1 · shares: Represents the number of shares of Issuer common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 9,250 Restricted Stock Units ("RSUs") on January 10, 2021. This sale is mandated by the Issuer's election under its 2013 Stock Incentive Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $4.196 to $4.21 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Of the reported securities beneficially owned, 44,625 shares are represented by unvested RSUs. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 19:00 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 95,000 | $0.00 Strike: $4.28 | $0.00 |
DisclosureSEC source: 0001179110-21-000560 · edgar.xml · derivative · entry 2 MILANO VINCENT · CIK 0001187159 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2031-01-08 F4 · derivative.exercise_date: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 8, 2021. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 8, 2022 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| January 05, 2021 Filed Jan 11, 2021 20:09 UTC | Aceragen, Inc. IDRA · Entity 110652 | SaleCommon Stock | 2,740 | $3.91 | $10,699.97 |
DisclosureSEC source: 0001179110-21-000524 · edgar.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,821 F1 · shares: Represents the number of shares of Issuer common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 8,438 Restricted Stock Units ("RSUs") on January 3, 2021. This sale is mandated by the Issuer's election under its 2013 Stock Incentive Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $3.90 to $3.93 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Of the reported securities beneficially owned, 53,875 shares are represented by unvested RSUs. Read SEC document |
| December 22, 2020 Filed Dec 22, 2020 18:45 UTC | Aceragen, Inc. IDRA · Entity 110652 | SaleCommon Stock | 37,169 | $4.32 | $160,525.48 |
DisclosureSEC source: 0001179110-20-012194 · edgar.xml · nonDerivative · entry 2 MILANO VINCENT · CIK 0001187159 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,561 F2 · shares: The sales represent the sale of shares necessary to meet tax withholding obligations in connection with the settlement of the RSUs, and were effected pursuant to a Rule 10b5-1 trading plan adopted between the Company and the Reporting Person on September 30, 2020. The sales do not represent a discretionary trade by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $4.18 to $4.54 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · balance_after: Of the reported securities beneficially owned, 62,313 shares are represented by unvested RSUs. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 18:45 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantCommon Stock | 128,170 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-012194 · edgar.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,730 F1 · shares: As previously disclosed in the Company's securities filings, on December 18, 2020 (the "Grant Date"), Reporting Person received an award of restricted stock units ("RSUs") in lieu of salary pursuant to a January 10, 2020 amendment to Reporting Person's employment agreement, granted consistent with Issuer's 2013 Stock Incentive Plan. Each RSU represents the right to receive one share of common stock of the Issuer. The RSUs were fully vested on the Grant Date. F4 · balance_after: Of the reported securities beneficially owned, 62,313 shares are represented by unvested RSUs. Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 16:34 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 92,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001179110-20-008427 · edgar.xml · derivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,000 Underlying: Common Stock · 92,000 shares Expires 2030-07-21 F1 · derivative.exercise_date: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on July 21, 2020. Twenty-five percent (25%) of the stock option vests and becomes exercisable on July 21, 2021 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 21:24 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantOption Grant (right to buy) · Derivative | 16,500 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001209191-20-035025 · doc4.xml · derivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2030-06-03 F1 · derivative.exercise_date: The shares subject this option will vest in twelve equal monthly installments commencing July 4, 2020, subject to Reporting Person's continuous service through each such date. Read SEC document |
| January 10, 2020 Filed Jan 14, 2020 18:19 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 92,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001179110-20-000562 · edgar.xml · derivative · entry 2 MILANO VINCENT · CIK 0001187159 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,000 Underlying: Common Stock · 92,000 shares Expires 2030-01-10 F3 · derivative.exercise_date: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 10, 2020. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 10, 2021 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| January 10, 2020 Filed Jan 14, 2020 18:19 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantCommon Stock | 37,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-000562 · edgar.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,560 F1 · shares: Represents a restricted stock unit ("RSU") award granted under the Issuer's 2013 Stock Incentive Plan. Each RSU represents a right to receive one share of Issuer common stock. The RSU award vests over a four-year period commencing on January 10, 2020. Twenty-five percent (25%) of the shares subject to the RSU award shall vest on each one-year anniversary of the grant date of the award. F2 · balance_after: Securities beneficially owned totaling 123,560 includes 61,247 shares of Issuer common stock owned and 62,313 of unvested RSU's held by the reporting person. Read SEC document |
| January 07, 2020 Filed Jan 9, 2020 21:39 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantStock Option (right to buy) · Derivative | 22,000 | $0.00 Strike: $1.85 | $0.00 |
DisclosureSEC source: 0001209191-20-002767 · doc4.xml · derivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2030-01-06 F1 · shares: This grant was made pursuant to the issuer's second amended and restated non-employee director compensation policy. F2 · derivative.exercise_date: The shares subject to this stock option will vest in thirty-six (36) equal monthly installments commencing on the one-month anniversary of January 7, 2020, subject to the reporting person's continuous service through each vesting date. Read SEC document |
| January 07, 2020 Filed Jan 10, 2020 08:14 UTC | Aceragen, Inc. IDRA · Entity 110652 | SaleCommon Stock | 3,006 | $1.78 | $5,351.88 |
DisclosureSEC source: 0001179110-20-000449 · edgar.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,560 F1 · shares: Represents the number of shares of Issuer common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 8,437 Restricted Stock Units ("RSUs") on January 3, 2020. This sale is mandated by the Issuer's election under its 2013 Stock Incentive Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $1.76 to $1.82 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Of the reported shares, 25,313 shares are represented by unvested RSUs. Read SEC document |
| January 07, 2020 Filed Jan 14, 2020 18:05 UTC Amendment | Aceragen, Inc. IDRA · Entity 110652 | SaleCommon Stock | 3,006 | $1.78 | $5,351.88 |
DisclosureSEC source: 0001179110-20-000555 · edgar.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,560 F1 · deemedExecutionDate: The Form 4 filed on January 10, 2020 did not include the Deemed Execution Date in Column 2A and corresponding footnote disclosure. This amendment to the Form 4 is being filed to include this information for the reported transaction. F2 · deemedExecutionDate: In accordance with terms of the RSU agreement, the "sell to cover" provision is intended to comply with the requirements of Rule 10b5-1(c)(1) under the Exchange Act and be interpreted to comply with the requirements of Rule 10b5-1(c) under the Exchange Act. F3 · shares: Represents the number of shares of Issuer common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 8,437 Restricted Stock Units ("RSUs") on January 3, 2020. This sale is mandated by the Issuer's election under its 2013 Stock Incentive Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F4 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $1.76 to $1.82 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · balance_after: Of the reported shares, 25,313 shares are represented by unvested RSUs. Read SEC document |
| December 17, 2019 Filed Dec 17, 2019 21:49 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Disposition to issuerStock Option (Right to Buy) · Derivative | 37,203 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0000899243-19-029444 · doc4.xml · derivative · entry 5 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,203 shares Expires 2024-08-11 F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. Read SEC document |
| December 17, 2019 Filed Dec 17, 2019 21:49 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Disposition to issuerStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $56.22 | $0.00 |
DisclosureSEC source: 0000899243-19-029444 · doc4.xml · derivative · entry 4 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2026-05-31 F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. Read SEC document |
| December 17, 2019 Filed Dec 17, 2019 21:49 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Disposition to issuerStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $50.93 | $0.00 |
DisclosureSEC source: 0000899243-19-029444 · doc4.xml · derivative · entry 3 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2027-05-30 F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. Read SEC document |
| December 17, 2019 Filed Dec 17, 2019 21:49 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Disposition to issuerStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $81.53 | $0.00 |
DisclosureSEC source: 0000899243-19-029444 · doc4.xml · derivative · entry 2 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2028-05-29 F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. Read SEC document |
| December 17, 2019 Filed Dec 17, 2019 21:49 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | OtherCommon Stock | 3,000 | $114.50 | $343,500.00 |
DisclosureSEC source: 0000899243-19-029444 · doc4.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. Read SEC document |
| July 09, 2019 Filed Jul 11, 2019 17:13 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 84,500 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001179110-19-008592 · edgar.xml · derivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,500 Underlying: Common Stock · 84,500 shares Expires 2029-07-09 F1 · derivative.exercise_date: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on July 9, 2019. Twenty-five percent (25%) of the stock option vests and becomes exercisable on July 9, 2020 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 20:17 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionRestricted Stock Units · Derivative | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001609351-19-000057 · wf-form4_155959305330570.xml · derivative · entry 2 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutics, Inc. common stock. F3 · derivative.exercise_date: On May 30, 2018, the reporting person was granted 1,500 restricted stock units that vest on the one-year anniversary of the grant date. Vested shares are delivered to the reporting person on the vesting date. F3 · derivative.expiration_date: On May 30, 2018, the reporting person was granted 1,500 restricted stock units that vest on the one-year anniversary of the grant date. Vested shares are delivered to the reporting person on the vesting date. Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 20:17 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionCommon Stock | 1,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001609351-19-000057 · wf-form4_155959305330570.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit converted into one share of Spark Therapeutics, Inc. common stock. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 20:11 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 84,500 | $0.00 Strike: $3.14 | $0.00 |
DisclosureSEC source: 0001179110-19-000526 · edgar.xml · derivative · entry 2 MILANO VINCENT · CIK 0001187159 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,500 Underlying: Common Stock · 84,500 shares Expires 2029-01-03 F3 · derivative.exercise_date: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 3, 2019. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 3, 2020 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 20:11 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantCommon Stock | 33,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-000526 · edgar.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,566 F1 · shares: Represents a restricted stock unit ("RSU") award granted under the Issuer's 2013 Stock Incentive Plan. Each RSU represents a right to receive one share of Issuer common stock. The RSU award vests over a four-year period commencing on January 3, 2019. Twenty-five percent (25%) of the shares subject to the RSU award shall vest on each one-year anniversary of the grant date of the award. F2 · balance_after: Securities beneficially owned totaling 89,566 includes 55,816 shares of Issuer common stock owned and 33,750 of unvested RSU's held by the reporting person. Read SEC document |
| December 24, 2018 Filed Dec 26, 2018 09:21 UTC | Aceragen, Inc. IDRA · Entity 110652 | PurchaseCommon Stock | 15,000 | $2.93 | $43,923.00 |
DisclosureSEC source: 0001179110-18-014244 · edgar.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,816 F1 · price: The price reported represents the weighted average sales price of shares purchased in multiple transactions at prices ranging from $2.92 to $2.945 per share. The reporting person hereby undertakes, upon the request of the Staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 13, 2018 Filed Aug 15, 2018 16:32 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option · Derivative | 65,000 | $0.00 Strike: $7.39 | $0.00 |
DisclosureSEC source: 0001104659-18-052292 · a4.xml · derivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2028-08-13 F1 · derivative.exercise_date: This option was granted under the Company's 2013 Stock Incentive Plan. The option vests with respect to 25% of the underlying shares on the first anniversary of the date of grant and the balance of the underlying shares vest in twelve equal quarterly installments following the first anniversary of the date of grant. Read SEC document |
| August 07, 2018 Filed Aug 8, 2018 19:35 UTC | Aceragen, Inc. IDRA · Entity 110652 | PurchaseCommon Stock | 10,000 | $5.51 | $55,100.00 |
DisclosureSEC source: 0001104659-18-050624 · a4.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,816 F1 · price: The price reported represents the weighted average sales price of shares purchased in multiple transactions at prices ranging from $5.49 to $5.52 per share. The reporting person hereby undertakes, upon the request of the Staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. F2 · balance_after: Reflects the issuer's 1-for-8 reverse stock split effected on July 27, 2018. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 20:30 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $18.30 | $0.00 |
DisclosureSEC source: 0000899243-18-016770 · doc4.xml · derivative · entry 2 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-06-12 F2 · derivative.exercise_date: This option vests and becomes exercisable with respect to 100% of the option shares on June 13, 2019, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 20:30 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-016770 · doc4.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 13, 2019, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| May 31, 2018 Filed Jun 1, 2018 01:32 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionRestricted Stock Units · Derivative | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001609351-18-000056 · wf-form4_152781671772170.xml · derivative · entry 4 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutics, Inc. common stock. F5 · derivative.exercise_date: On May 31, 2017, the reporting person was granted 1,500 restricted stock units that vest on the one-year anniversary of the grant date. Vested shares are delivered to the reporting person on the vesting date. F5 · derivative.expiration_date: On May 31, 2017, the reporting person was granted 1,500 restricted stock units that vest on the one-year anniversary of the grant date. Vested shares are delivered to the reporting person on the vesting date. Read SEC document |
| May 31, 2018 Filed Jun 1, 2018 01:32 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionCommon Stock | 1,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001609351-18-000056 · wf-form4_152781671772170.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit converted into one share of Spark Therapeutics, Inc. common stock. Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 01:32 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | GrantRestricted Stock Units · Derivative | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001609351-18-000056 · wf-form4_152781671772170.xml · derivative · entry 3 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutics, Inc. common stock. F4 · derivative.exercise_date: 100% of the restricted stock units vest on the one-year anniversary of the grant date. Vested shares will be delivered to the reporting person on the vesting date. F4 · derivative.expiration_date: 100% of the restricted stock units vest on the one-year anniversary of the grant date. Vested shares will be delivered to the reporting person on the vesting date. Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 01:32 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | GrantStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $81.53 | $0.00 |
DisclosureSEC source: 0001609351-18-000056 · wf-form4_152781671772170.xml · derivative · entry 2 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2028-05-29 F2 · derivative.exercise_date: 100% of the shares vest on the one-year anniversary of the grant date. Read SEC document |
| January 03, 2018 Filed Jan 5, 2018 16:22 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option · Derivative | 600,000 | $2.24 Strike: $2.24 | $1,344,000.00 |
DisclosureSEC source: 0001179110-18-000591 · edgar.xml · derivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2028-01-03 F1 · derivative.exercise_date: This option was granted under the Company's 2013 Stock Incentive Plan. The options vest with respect to 25% of the underlying shares on the first anniversary of the date of grant and the balance of the underlying shares vest in twelve equal quarterly installments following the first anniversary of the date of grant. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 21:10 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $13.75 | $0.00 |
DisclosureSEC source: 0001209191-17-040882 · doc4.xml · derivative · entry 2 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-06-14 F2 · derivative.exercise_date: This option vests and becomes exercisable with respect to 100% of the option shares on June 15, 2018, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 21:10 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-040882 · doc4.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 15, 2018, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| May 31, 2017 Filed Jun 2, 2017 20:05 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | GrantRestricted Stock Units · Derivative | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001609351-17-000046 · wf-form4_149643389367660.xml · derivative · entry 2 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutics Inc. common stock. F3 · derivative.exercise_date: 100% of the restricted stock units vest on the one-year anniversary of the grant date. Vested shares will be delivered to the reporting person on the vesting date. F3 · derivative.expiration_date: 100% of the restricted stock units vest on the one-year anniversary of the grant date. Vested shares will be delivered to the reporting person on the vesting date. Read SEC document |
| May 31, 2017 Filed Jun 2, 2017 20:05 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | GrantStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $50.93 | $0.00 |
DisclosureSEC source: 0001609351-17-000046 · wf-form4_149643389367660.xml · derivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2027-05-30 F1 · derivative.exercise_date: 100% of the shares vest on the one-year anniversary of the grant date. Read SEC document |
| January 03, 2017 Filed Jan 6, 2017 16:23 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option · Derivative | 300,000 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001179110-17-000643 · edgar.xml · derivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2027-01-03 F1 · derivative.exercise_date: This option was granted under the Company's 2013 Stock Incentive Plan. The options vest with respect to 25% of the underlying shares on the first anniversary of the date of grant and the balance of the underlying shares vest in twelve equal quarterly installments following the first anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.